2015
DOI: 10.1016/j.jbspin.2014.12.004
|View full text |Cite
|
Sign up to set email alerts
|

Spondyloarthritis and the gut: A new look

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
7
0

Year Published

2015
2015
2017
2017

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 24 publications
0
7
0
Order By: Relevance
“…attempted to address these issues with a combined human/rabbit study. The human component showed growth in only three of 30 discs (cultured for 10 days), none P. acnes ; the rabbits verified that “ P. acnes could infect the degenerated lumbar discs by way of bacteremia.” 39 Finally, a recent editorial addressing the present understanding of spondyloarthritis and gut microbiota noted that evaluating, and trying to modulate gut microbiota is a very complex undertaking; however, various rheumatologic conditions may be associated with distinct bacterial profiles 40 …”
Section: Discussionmentioning
confidence: 99%
“…attempted to address these issues with a combined human/rabbit study. The human component showed growth in only three of 30 discs (cultured for 10 days), none P. acnes ; the rabbits verified that “ P. acnes could infect the degenerated lumbar discs by way of bacteremia.” 39 Finally, a recent editorial addressing the present understanding of spondyloarthritis and gut microbiota noted that evaluating, and trying to modulate gut microbiota is a very complex undertaking; however, various rheumatologic conditions may be associated with distinct bacterial profiles 40 …”
Section: Discussionmentioning
confidence: 99%
“…The presence of (microscopic) gut inflammation appears relevant for prognosis and therapeutic decision making as SpA patients with a chronic type of gut inflammation have a less favourable disease course. Therefore, faecal calprotectin analysis is part of the clinical diagnostic work-up of SpA patients [28]. In our study, 26 consecutive rheumatologic patients (24.8%) were included.…”
Section: Methodsmentioning
confidence: 99%
“…In the same way, the impact of this treatment on extra rheumatologic manifestations is important, since they are part of the general presentation of the disease. In non-AS patients, secukinumab showed beneficial effect on uveitis (with high doses) [10], and on skin psoriasis [11]; but the results in Crohn's disease were disappointing [12], even if there are clear connections between gut inflammation and axial spondyloarthritis [13].…”
Section: Daniel Wendlingmentioning
confidence: 99%